Skin toxicity is a frequent complication of anti-epidermal growth factor receptor therapy, which can be an obstacle in maintaining the dose intensity and may negatively impact on the clinical outcome of cancer patients. Skin lesions depend on the disruption of the keratinocyte development pathways and no treatment is clearly effective in resolving the cutaneous alterations frequently found during antiepidermal growth factor receptor therapy. Among systemic treatments, oral tetracycline proved to be useful in preventing skin manifestations. We describe the case of a patient affected by metastatic colorectal cancer, for whom a combination of chemotherapy and cetuximab was used as second-line treatment. The patient developed a symptomatic papu...
WOS: 000249007200006PubMed ID: 17641540Background: Cetuximab is a member of a new family of antineop...
There is a variety of adverse effects and toxicities of newer and older chemotherapeutic agents whic...
T reatment of many types of tumors has evolved from chemotherapy to a more personalized approach, us...
The use of targeted therapies, when added to conventional chemotherapy, has significantly improved c...
Targeted anticancer therapies, unlike the traditional cytotoxic chemotherapies which lead to systemi...
Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inh...
Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including th...
Cetuximab (CTX) is a monoclonal antibody against the epidermal growth factor receptor (EGFR). It is ...
Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and ...
Target therapy, using drugs inhibiting specific cell surface receptors, represents a new oncologic a...
Abstract Background: Antibodies against the epidermal growth factor receptor (EGFR), such as cetuxim...
Inhibition of the epidermal growth factor receptor (EGFR) represents one of the most important avenu...
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that targets the extracellular d...
The last few years, new therapies targeting the epidermal growth factor receptor (EGFR) have shown t...
Copyright © 2012 Shaad E. Abdullah et al. This is an open access article distributed under the Creat...
WOS: 000249007200006PubMed ID: 17641540Background: Cetuximab is a member of a new family of antineop...
There is a variety of adverse effects and toxicities of newer and older chemotherapeutic agents whic...
T reatment of many types of tumors has evolved from chemotherapy to a more personalized approach, us...
The use of targeted therapies, when added to conventional chemotherapy, has significantly improved c...
Targeted anticancer therapies, unlike the traditional cytotoxic chemotherapies which lead to systemi...
Cutaneous toxicity is the most evident adverse effect of epidermal growth factor receptor (EGFR) inh...
Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including th...
Cetuximab (CTX) is a monoclonal antibody against the epidermal growth factor receptor (EGFR). It is ...
Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and ...
Target therapy, using drugs inhibiting specific cell surface receptors, represents a new oncologic a...
Abstract Background: Antibodies against the epidermal growth factor receptor (EGFR), such as cetuxim...
Inhibition of the epidermal growth factor receptor (EGFR) represents one of the most important avenu...
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that targets the extracellular d...
The last few years, new therapies targeting the epidermal growth factor receptor (EGFR) have shown t...
Copyright © 2012 Shaad E. Abdullah et al. This is an open access article distributed under the Creat...
WOS: 000249007200006PubMed ID: 17641540Background: Cetuximab is a member of a new family of antineop...
There is a variety of adverse effects and toxicities of newer and older chemotherapeutic agents whic...
T reatment of many types of tumors has evolved from chemotherapy to a more personalized approach, us...